-DR. TISHA VYAS Assistant Professor, Head Biotechnology Department C. U. Shah Institute of Science CONTENT

• LEADING INDUSTRIES IN • QUESTIONS STATES • REFERENCES • ROLES OF US PROMOTION AGENCIES IN BIOTECHNOLOGY • GOVERNMENT POLICIES FOR BIOTECHNOLOGY • BIOTECHNOLOGY (BT) POLICY • ICGEB • DBT • GSBTM • CSIR

-DR. TISHA VYAS INTRODUCTION • Amongst the countries of the world, India is amongst the top 12 biotech destinations. • Biotech industry is increasing due to: increasing economic prosperity, health consciousness and a billion-plus population base.

-DR. TISHA VYAS INTIATIVES BY GOVERNMENT OF INDIA

• Launch of NATIONAL RURAL HEALTHCARE MISSION to boost healthcare. • Department of Biotechnology (DBT) has designed NATIONAL BIOTECHNOLOGY DEVELOPMENT STRATEGY (NBDS) to strengthen human resources and infrastructure. • FOREIGN DIRECT INVESTMENT (FDI)- for promotion of manufacturing of drugs and pharmaceuticals

-DR. TISHA VYAS BIOCON

• LEADING INDUSTRIES IN STATES A.BIOCON B.SERUM INSTITUE OF INDIA C.ZYDUS D.PANACEA BIOTEC • ROLES OF US PROMOTION AGENCIES IN BIOTECHNOLOGY • GOVERNMENT POLICIES FOR BIOTECHNOLOGY • BIOTECHNOLOGY (BT) POLICY • ICGEB • DBT • GSBTM • CSIR

-DR. TISHA VYAS -DR. TISHA VYAS -DR. TISHA VYAS -DR. TISHA VYAS -DR. TISHA VYAS -DR. TISHA VYAS -DR. TISHA VYAS SERUM INSTITUE OF INDIA • Serum Institute of India is a manufacturer of immunobiological drugs including vaccines in India. • It was founded by Cyrus Poonawalla in 1966. • The company is a subsidiary of the holding company Poonawalla Investment & Industries, • LEADING INDUSTRIES IN STATES founded in 1966 and controlled by billionaire Cyrus A.BIOCON Poonawalla. B.SERUM INSTITUE OF INDIA • The company is the world's largest vaccine C.ZYDUS producer by number of doses produced. D.PANACEA BIOTEC • The company produces around 1.3 billion doses of • ROLES OF US PROMOTION AGENCIES IN BIOTECHNOLOGY vaccines each year.

• GOVERNMENT POLICIES FOR • In 2020 the pharmaceutical company AstraZeneca BIOTECHNOLOGY in collaboration with Oxford University is • BIOTECHNOLOGY (BT) POLICY contracting for 1 billion of the Institute's capacity • ICGEB for the COVID-19 vaccine. • DBT • The products developed include tuberculosis • GSBTM

• CSIR vaccine Tubervac (BCG), Poliovac for poliomyelitis, DTP, MMR and other vaccinations for -DR. TISHA VYAS the childhood vaccination schedule. -DR. TISHA VYAS -DR. TISHA VYAS -DR. TISHA VYAS • Cadila was founded in 1952 by Ramanbhai Patel (1925– 2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. • It evolved over the next four decades into an established pharmaceutical company. • In 1995 the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals Ltd., and Cadila Healthcare Ltd • LEADING INDUSTRIES IN STATES became the Patel family's holding company. A.BIOCON • In 2010, Cadila Healthcare received a Welcome Trust B.SERUM INSTITUE OF INDIA Award under the "R&D for Affordable Healthcare in C.ZYDUS India" initiative. D.PANACEA BIOTEC • In 2014, Cadila Healthcare launched the world's first • ROLES OF US PROMOTION adalimumab biosimilar under the brand name AGENCIES IN BIOTECHNOLOGY Exemptia at one-fifth the originator's price. • GOVERNMENT POLICIES FOR • Zydus Cadila Healthcare has also launched its first BIOTECHNOLOGY research based drug molecule Saroglitazar in • BIOTECHNOLOGY (BT) POLICY treatment of Diabetic Dyslipidemia "Lipaglyn". • ICGEB • SoviHep is the first sofosbuvir brand launched in India • DBT by Zydus in year 2015. • GSBTM • In 2019, injectable ketorolac tromethamine • CSIR manufactured by Zydus (Cadila Healthcare) was

-DR. TISHA VYAS recalled due to microbial growth. • Good health, happiness, joy, growth, togetherness, discovery, learning, exploration, evolution, transformation, aspirations, are all intrinsically linked with life. • Zydus is dedicated to all these dimensions. Zydus Srishti, the group’s CSR programme, is about reaching out to make a difference in a myriad ways in the areas of Health – Swaasthya, Education – Shiksha, Research – Shodh and Outreach – Saath. • Through these initiatives, the group reaches out to the community that it forms a part of, finding new expressions for its mission to create healthier communities globally. • The group has forged meaningful partnerships with its key stakeholders both internal and external, partners in progress and the community at large. • Ethical practices, accountability, robust governance and sustainable initiatives are at the very core of the group’s business strategy, planning and operations which helps minimise risks and leverage opportunities to create value. • The group’s philosophy for community engagement is based on the principle of volunteerism and is an intensive, comprehensive and sustainable programme.

-DR. TISHA VYAS -DR. TISHA VYAS -DR. TISHA VYAS Panacea Biotec • LEADING INDUSTRIES IN • Panacea Biotec claims to be the largest vaccine STATES manufacturing company in India. A.BIOCON • Panacea Biotec has introduced the next B.SERUM INSTITUE OF INDIA generation inactivated polio vaccine (eIPV) via a C.ZYDUS D.PANACEA BIOTEC collaboration with the Netherland Vaccine Institute. • ROLES OF US PROMOTION AGENCIES IN • BIOTECHNOLOGY This vaccine has found extensive usage in India • GOVERNMENT POLICIES FOR for more than three years now and is registered BIOTECHNOLOGY in Bangladesh. • BIOTECHNOLOGY (BT) POLICY • IPV is also in an advanced stage of registration • ICGEB in 10 countries worldwide, with the target of • DBT being in more than 30 countries in a couple of • GSBTM years, and has been put up for WHO • CSIR prequalification, which is expected soon

-DR. TISHA VYAS Panacea Biotec timeline:

1984 - Panacea Drug (P) Ltd. was formed 1988 - Established a plant for vaccines production at New Delhi, under the name Radicura Pharma 1989 - Pharmaceutical formulations plant at New Delhi, under the name Panacea Drug P Ltd. 1993 - Merger of Panacea Drugs (P) Ltd. and Radicura Pharma to form Panacea Biotec Ltd. 1995 - IPO of equity shares of Rs.180 million 1995 - State-of-the-art drug delivery R&D centre at Lalru 1997 - First product patent in several countries 2001 - R&D tie up with European MNC 2002 - In-licensing agreement with Biotechnology Consortium of India for development and commercialization of anthrax vaccine 2002 - Commissioning of a recombinant vaccine production plant 2004 - In-licensing agreement with the National Institute of Immunology, New Delhi, for Japanese encephalitis candidate vaccine 2004 - Marketing joint venture with Chiron (now Novartis) Vaccines, UK 2004 - Collaboration with Cambridge Bio-stability, UK, for thermo stable vaccines 2005 - In-licensing agreement with National Institute of Health, US for a hair growth hormone -DR. TISHA VYAS • 2006 - WHO cGMP complaint ultra modern pharmaceuticals formulation facility at Baddi, Himachal Pradesh • Landmark collaborations with the Netherlands Vaccine Institute (the Nederlands Vaccin Instituut (NVI)) for manufacture and marketing of a finished inactivated polio Vaccine (IPV) and a number of IPV-based combination vaccines in India and across the globe • Collaboration with PT.Bio Farma to manufacture and market a measles vaccine • Inauguration of Biopharmaceutical R&D Centre at New Delhi • Pre-qualification certification from WHO for supply of recombinant hepatitis-B vaccine to UN agencies • Collaboration with National Research Development Corporation (NRDC) for technology transfer of foot and mouth vaccine • 2007 - Vaccine formulation plant at Baddi • Research agreement with Punjab University to develop new chemical entities for psychiatric disorders • 2008 - Foray into healthcare delivery – collaboration to set up a 220-bed multi super-specialty hospital in NCR • WHO prequalification for fully liquid innovative combination pentavalent vaccine, EasyFive against five deadly infectious diseases (DTwP+ Hep B+ Hib) of early childhood • 2011 - WHO disqualified 3 of Panacea vaccines after inspection at Lalru centre in Punjab and put all shipments on hold. Earlier in 2009 the company had bagged the WHO contract for supplying vaccines -DR. TISHA VYAS Questions 1. Give a detailed description of BIOCON as a leading industry. 2. Describe the history of Zydus wellness and healthcare. 3. Show the events that took place in the development of Panacea biotech. 4. Note down the historical timeline of Serum Institute of India and its different initiatives across India. References • Panacea biotech official website • Zydus official website • BIOCON official website • Serum Institute of India official website

-DR. TISHA VYAS -DR. TISHA VYAS